Table 3.
N. gonorrhoeae strains with ceftriaxone MIC ≥ 0.5 mg/L
| Country | Year | Strain | ST NG-MAST | Genogroup NG-MAST | ST MLST | ST NG-STAR | PenA | CTX MIC mg/L |
|---|---|---|---|---|---|---|---|---|
| Ireland | 2018 | IR72 | 17,842 | G564 | 1903 | 1133 | 60.001 | 0.5 |
| Australia | 2018 | A2543* | 16,848 | G1866 | 12,039 | 996 | 64.001 | 0.5 |
| England | 2018 | G97687* | 16,848 | G1866 | 12,039 | 996 | 64.001 | 0.5 |
| England | 2018 | G7944* | 16,848 | G1866 | 12,039 | 996 | 64.001 | 0.5 |
| France | 2017 | F90 | 3435 | G564 | 1903 | 133 | 60.001 | 0.5 |
| Denmark | 2017 | GK124 | 1614 | G5267 | 1903 | ND | ND | 0.5 |
| Canada | 2017 | 47,707 | 1614 | G5267 | 1903 | 233 | 60.001 | 1.0 |
| Australia | 2017 | A7536 | 15,925 | G11110 | 1903 | 233 | 60.001 | 0.5 |
| Australia | 2017 | A7846 | 1614 | G5267 | 1903 | 233 | 60.001 | 0.5 |
| Japan | 2015 | FC428 | 3435 | G564 | 1903 | 233 | 60.001 | 0.5 |
| Japan | 2015 | FC460 | 3435 | G564 | 1903 | 233 | 60.001 | 0.5 |
| Japan | 2014 | GU140106 | 6543 | G11018 | 7363 | ND | ND | 0.5 |
| Argentina | 2014 | CCETS-7069 | 13,064 | G21 | 13,637 | 139 | IX | 0.5 |
| Australia | 2013 | A8806; WHO-Z | 4015 | G11018 | 7363 | 227 | 64.001 | 0.5 |
| China | 2012/13 | GD4 | 10,208 | G5062 | ND | ND | II | 0.5 |
| China | 2012/13 | GX1 | 11,129 | ND | ND | ND | XXI | 0.5 |
| China | 2012/13 | HN9 | 5913 | G1791 | ND | ND | XXI | 0.5 |
| Spain | 2012 | F89; WHO-Y | 1407 | G1407 | 1901 | 16 | 42.001 | 1.0 |
| France | 2010 | F89; WHO-Y | 1407 | G1407 | 1901 | 16 | 42.001 | 1.0 |
| Japan | 2009 | HO41;WHO-X | 4220 | G4019 | 7363 | 226 | 37.001 | 2.0 |
| China | 2007 | ND | 2288 | G1791 | ND | ND | XVII | 0.5 |
ND not done, CTX ceftriaxone
*Azithromycin resistance, MIC > 256 mg/L